RxSight, Inc.

Hello and thank you for standing by. My name is John and I will be your conference operator today. At this time, I would like to welcome everyone to the RxSight preliminary second quarter financial results and product pipeline updates following collaboration agreement. All lights have been placed in mute to prevent any background noise. After the speaker remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. And to withdraw your question, simply press star one again. I would now like to turn the conference over to Oliver Moravcevic, VP of Investor Relations. Please go ahead.

Thank you, Operator. With me on the call this morning is RxSight President and Chief Executive Officer, Dr. Ron Kurtz, and Chief Financial Officer, Mark Wilterly. Yesterday, RxSight released a pair of press releases, one reporting on a new collaboration agreement with Alcon, and the second reporting preliminary revenue results for the three months ending June 30, 2026. updated product pipeline, and revised folio guidance. Copies of both press releases and corresponding 8Ks are available on the company's website. Before we begin, I would like to inform you that comments and responses to questions during today's call reflect management's views as of today, July 7, 2026, and will include forward-looking and opinion statements including predictions, estimates, plans, expectations, and other information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are more fully described in our press release issued yesterday and in our filings with the Securities and Exchange Commission or SEC. Investors are cautioned not to place undue reliance on forward-looking statements and will disclaim any obligation to update or revise these forward-looking statements except as may be required by law. During today's call, we will discuss certain non-GAAP financial measures. I would also like to remind you that the preliminary results discussed on our call today are estimates and that our complete unaudited financial results for the second quarter of 2026, which are subject to the review of our independent auditor, are expected to be announced on Wednesday, August 5, 2026. Please note that this conference call will be available for audio replay on our investor relations website. With that, I'll turn the call over to Ron.

Good morning and thank you for joining us. Over the last several years, the RxSight team has been developing proprietary hybrid IOL materials for next generation light adjustable technology that can support a full suite of adjustable lenses across all premium categories. Designed to enable expanded patient choice and customization, along with a reduction in required postoperative treatments, these developments are being pursued both via our standalone product pipeline and through our collaboration with Alcon. RxSight's next-generation adjustable IOLs will build upon the quality of vision that has been a key attraction for LAL patients for many years. Our partnership with Alcon aims to leverage each company's expertise to develop adjustable presbyopia correcting IOLs that, for the first time, will enable doctors to refine visual outcomes noninvasively after surgery for patients who choose a PCIOL. Taken together, these technology-driven strategic initiatives solidify RxSight's position as the leader in postoperative adjustability, create a platform for high-margin future growth, and Accelerate expansion across a wider base of patients. While we believe these strategic developments will be key multi-year growth drivers for RxSight, last night's announcement also detailed the near-term challenges we experienced in the second quarter after several quarters of relatively stable utilization trends. Although we do not yet have Q2 data from other premium IOLs, We believe this retrenchment is linked to widespread competitive trialing activity associated with new product launches. While the LAL value proposition remains highly differentiated, these trial programs provide a significant short-term incentive to an already strained practice environment. While the effects of competitive trialing tend to wane as doctors determine the true value of a new offering based on their own clinical experience, We expect the heightened competitive environment to remain active through the end of the year. We also note that consumer sentiment remained under pressure, which we believe could have contributed to more deliberate patient decision making and softer overall procedure activity. While cataract surgery typically cannot be deferred indefinitely, unusual declines in overall cataract volumes were observed in Q1 with patient confidence and the broader economic backdrop being two potential factors. We believe we can overcome these challenges by accelerating customer re-engagement efforts that have shown success in targeted rollouts, and we are excited to be making additional investments in our U.S. LAL sales force to expand our depth of penetration within accounts. coupled with our technologies unparalleled clinical outcomes, we remain confident in our team's ability to navigate these headwinds successfully. I'll now turn it over to Mark to provide select financial metrics related to our second quarter performance and updated thoughts on our full year 2026 outlook.